Olema Pharmaceuticals, Inc. OLMA 深 滬
等待開盤 08-13 09:30:00 美东时间
5.15
+0.580
+12.69%
華盛通- 最 高5.58
- 今 開5.00
- 成交量 105.70万股
- 最 低 4.92
- 昨 收 4.57
- 總市值 3.52亿
- 52周最高 13.93
- 市盈率 靜 --
- 換手率 1.54%
- 52周最低 2.86
- 委 比 -33.43%
- 總股本 6842.13万
- 歷史最高 60.27
- 量 比 2.63
- 振 幅 14.44%
- 歷史最低 2.00
- 每 手 1
- 風險率 3.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Olema Pharmaceuticals shares are trading higher. The company reported Q2 financial results.
Olema Pharmaceuticals shares are trading higher. The company reported Q2 financ...
08-12 21:00
Citigroup Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $21
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target from $20 to $21.
08-12 19:28
Olema Pharmaceuticals Q2 EPS $(0.51) Misses $(0.38) Estimate
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.38) by 35.64 percent. This is a 5.56 percent increase over losses of $(0.54) per share
08-12 04:14
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
Olema Pharmaceuticals reported that the Phase 3 OPERA-01 trial with 90mg once-daily palazestrant continues enrollment, targeting top-line data in 2H 2026. The Phase 3 OPERA-02 trial in combination with ribociclib is set to begin in Q3 2025. Palazestrant's combination data with ribociclib will be presented at ESMO 2025. The company ended Q2 2025 with $361.9 million in cash and marketable securities.
08-11 20:01
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. granted stock options to 11 new employees for 322,000 shares, effective June 2, 2025, under its 2022 Inducement Plan. The options, priced at $4.38 per share, vest over four years with monthly installments and a 10-year term, in compliance with Nasdaq Listing Rule 5635(c)(4). The company focuses on targeted therapies for breast cancer, with key candidates in Phase 3 and Phase 1 trials.
06-03 20:30
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Lyra Therapeutics (NASDAQ:LYRA) stock rose 376.8% to $23.5 during Mond...
06-03 01:06
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
Olema Pharmaceuticals announced alignment with the FDA to select 90 mg of palazestrant for Part 2 of the Phase 3 OPERA-01 trial and the Phase 3 OPERA-02 trial in ER+/HER2- metastatic breast cancer. The update will be presented at the ASCO Annual Meeting on June 2. Palazestrant, a CERAN and SERD, shows promise in treating resistant breast cancers, with data expected in 2026 and a potential launch in 2027.
05-28 11:00
Oppenheimer Maintains Outperform on Olema Pharmaceuticals, Lowers Price Target to $22
Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and lowers the price target from $25 to $22.
05-14 22:28
Why Sable Offshore Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of Sable Offshore Corp. (NYSE:SOC) rose sharply in today's pre-market tr...
05-12 17:13
